Objectives: We determine adverse events following 4 doses of SARS-CoV-2 vaccine in those with inflammatory bowel disease (IBD), associations between antibodies and injection site reactions (ISR), and risk of IBD flare.
Methods: Individuals with IBD were interviewed for adverse events to SARS-CoV-2 vaccine. Multivariable linear regression assessed the association between antibody titres and ISR.
Results: Severe adverse events occurred in 0.03%. ISR was significantly associated with antibody levels following 4th dose (GMR= 2.56; 95% CI: 1.18, 5.57). No cases of IBD flare occurred.
Conclusions: SARS-CoV-2 vaccines are safe for those with IBD. ISRs following 4th dose may indicate increased antibodies.
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.